AzTrials
AzTrials

LaryngoscopyPhase 4NCT06037915

Airway Interventions During Intravenous Anesthesia in Children Undergoing Direct Laryngoscopy for Surgical Procedures Using High Flow Nasal Versus Low Flow Oxygen. A Pilot Study.(Flowkid)

A Phase 4 study testing low flow oxygen with nasopharyngeal tube and high flow oxygen with OptiflowTM Nasal High Flow in people with Laryngoscopy and Child, run by University Hospital, Antwerp at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to evaluate possible differences in airway responses and interventions during intravenous anesthesia for direct laryngoscopy in children when comparing two oxygenation methods (conventional low flow oxygen supplementation via nasopharyngeal tube versus Nasal High Flow Therapy with… Read more about this study

Who is it for?
Ages 1 month to 10 years
Conditions the study is for
Laryngoscopy, Child, Oxygen Therapy
What is being tested?
low flow oxygen with nasopharyngeal tube and high flow oxygen with OptiflowTM Nasal High Flow
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteBelgium
Study dates
28 Nov 2023to 16 May 2025
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 month to 10 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • scheduled for elective direct laryngoscopy with surgical intervention
  • written informed consent of the parents or legal guardian

Who cannot join

  • refusal of informed consent
  • known allergy for dexmedetomidine
  • known allergy for remifentanil
  • pulse oxygen saturation (SpO2) is lower than 85%, at induction of anesthesia

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • Antwerp University Hospital

    Edegem, Antwerp, 2650

Other trials in Belgium

About this study

Official title: Airway Interventions During Intravenous Anesthesia in Children Undergoing Direct Laryngoscopy for Surgical Procedures Using High Flow Nasal Versus Low Flow Oxygen. A Pilot Study.

The goal of this clinical trial is to evaluate possible differences in airway responses and interventions during intravenous anesthesia for direct laryngoscopy in children when comparing two oxygenation methods (conventional low flow oxygen supplementation via nasopharyngeal tube versus Nasal High Flow Therapy with the OptiflowTM system ).

Read the detailed description

Surgical procedures during direct laryngoscopy is performed under general anesthesia with spontaneous or controlled ventilation. These therapeutic procedures, such as the supraglottoplasty, are a challenge for both the surgeon and the anesthesiologist. While the airway should be freely accessible for the surgeon, the main concern of the anesthesiologist is adequate sedation, preservation of the free airway and oxygenation. Prevention of under-or over-sedation, with careful titration of sedation according to patient needs and preservation of spontaneous ventilation are challenging, especially in children.Traditionally low flow oxygen supplementation via nasopharyngeal tube was used for oxygenation during the surgery. However, it is known that 'in adults', the reported safe apnea time can be extended by using high flow nasal oxygen and this method is therefore increasingly used for oxygenation. Previous studies have already reported that the application of high-flow 100 percent(%) oxygen in children allowed for an apnea time of more than 7 minutes without desaturation. Interestingly, time to desaturation was not lowered when low-flow 100% oxygen via nasal cannula was used, compared to high flow oxygen.

The OptiflowTM Nasal High Flow (NHF) Therapy system (Fisher and Paykel Healthcare - Auckland New Zealand) is a form of non-invasive respiratory therapy (Fig.1). This system can deliver high levels of oxygen (FiO2 21% up to 100%). The higher flow rates provide a reduction of dead space and a dynamic, positive airway pressure, both of which can increase alveolar ventilation. A critical distinctive element of NHF therapy is airway hydration, i.e., heated humidification. Heating and humidifying not only makes high gas flows tolerable for patients but also prevents desiccation of the airway epithelium and maintains and improves mucociliary clearance.The Fisher \& Paykel Healthcare Optiflow Junior 2 Nasal Interface is a non-sealing nasal interface specifically designed for the flow requirements and anatomical features of neonates, infants and children on NHF therapy.

In this trial, minor participants scheduled for elective direct laryngoscopy with surgical intervention will be enrolled, provided that they comply with in-and exclusioncriteria and that an informed consent was given by the parent or legal guardian. All included children will be premedicated with midazolam 0.05 mg/kg. Standard monitoring including 3-lead electrocardiography, non-invasive blood pressure, peripheral pulse-oximetry, respiratory rate and rectal temperature will be continuously monitored and recorded. To evaluate the depth of sedation, the NeuroSENSE ® monitor will be installed previous to anesthesia induction. After induction of anesthesia a 24 Gauge intravenous catheter is placed in a peripheral vein. Baseline parameters of heart rate and blood pressure will be noted at this timepoint. Induction of anesthesia will be carried out with sevoflurane and a bolus of dexmedetomidine of 4mcg/kg will be administered. Maintenance of anesthesia will be accomplished with dexmedetomidine infused at 2mcg/kg/h and adjusted to clinical needs with top up rate dexmedetomedine of 0.5 mcg/kg/h. Remifentanil will be infused at 0.3 mcg/kg/min and adjusted to clinical needs to 0.5 mcg/kg/min.Guidance of the titration of dexmedetomidine/remifentanil according to clinical signs, is standard of care. Before start of surgery, on visualizing the vocal cords, one spray of 10% Lidocaïne is delivered to anesthetize the vocal cords. The included participants will be randomized into two groups: low flow oxygen vs high flow nasal therapy. The REDCap randomization module will be used to randomize patients. According to randomization, children will receive Optiflow nasal prongs or nasal pharyngeal tube for oxygen supplementation. Spontaneous ventilation will be maintained. In case of laryngospasm and desaturation, propofol will be used as rescue medication. After surgery all children will be monitored on intensive care or PACU (Post Anesthetic Care Unit) as standard of care.

Being tested
low flow oxygen with nasopharyngeal tube, high flow oxygen with OptiflowTM Nasal High Flow

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • low flow oxygen with nasopharyngeal tubeDevice

    low flow oxygen with nasopharyngeal tube

  • high flow oxygen with OptiflowTM Nasal High FlowDevice

    high flow oxygen with OptiflowTM Nasal High Flow

Study groups in NCT06037915
Study groupRoleWhat they receive
low flow oxygenActive comparatorNot described
Receives: Device: low flow oxygen with nasopharyngeal tube
high flow oxygenActive comparatorNot described
Receives: Device: high flow oxygen with OptiflowTM Nasal High Flow

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. the incidence of airway interventions

    defined as the need to interrupt the procedure in order to maintain adequate oxygenation with mask ventilation, introduction of a nasopharyngeal airway or intubation with endotracheal tube

    Measured: during surgery

  2. incidence of desaturation

    defined as pulse oxygen saturation(SpO2) lower than 90% for more than 30 seconds

    Measured: during surgery

  3. incidence of bradycardia

    defined as a change of 30 percent beyond the baseline of heart rate

    Measured: during surgery

  4. incidence of tachycardia

    defined as a change of 30 percent beyond the baseline of heart rate

    Measured: during surgery

Secondary outcomes (1)
  1. Comparison of the oropharyngeal mucosa before and after the procedure

    1= good quality, humid mucosa; 2= acceptable quality; 3= dry mucosa)

    Measured: before induction of anesthesia and at end of surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Sep 2023
  2. Study start28 Nov 2023
  3. Primary completion16 May 2025
  4. Study completion16 May 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06037915
Sponsor's protocol ID
003125
Status last verified
Jul 2025
First submitted
7 Sep 2023
Last updated
9 Jul 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing low flow oxygen with nasopharyngeal tube and high flow oxygen with OptiflowTM Nasal High Flow in people with Laryngoscopy and Child, run by University Hospital, Antwerp at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

the incidence of airway interventions (time frame: during surgery). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in